USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: VENATORX PHARMACEUTICALS, INC.
Address: 30 Spring Mill Drive
Malvern, PA 19355
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,800,000.00 3
SBIR Phase II $6,000,000.00 2

Award List:

Novel Metallo-beta-lactamase Inhibitors

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Luigi Xerri – 484-595-6990
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as NDM-1 are found on mobile genetic elements which are rapidly spreading in Enterobacteriaceae and… More

Preserving beta-lactam utility against pathogens producing all classes of beta-la

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Christopher J. Burns – 610-213-0248
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR Grant focuses on advancement of a new class of inhibitors of serine-based b-lactamases (Ambler classes A, C and D), for combination with the only subclass of b-lactams (the monobactams) that are not sensitive to zinc-based enzymes (Ambler Class… More

Novel Compounds Targeting Bacterial PBPs

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Christopher J. Burns – 610-213-0248
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR Application centers on a new class of non-??-lactam antibacterial agents that target the same biological target as the ?-lactam class of antibiotics (i.e., the Penicillin Binding Proteins, or PBPs), but with the prospect of avoiding n important… More

Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Luigi Xerri – 484-595-6990
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. While carbapenems are among the most prescribed antibiotics for infections caused by these organisms, carbapenem resistance conferred by zinc-based metallo-carbapenemases (Amber Class… More

Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Christopher J. Burns – 610-213-0248
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. This crisis has been further amplified by the recent emergence of the NDM-1 super-bug gene , a zinc-based metallo- -lactamase (Amber Class B), in Enterobacteriaceae. Members of… More